Trials / Completed
CompletedNCT04712734
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
An Open-label, Adaptive, Repeat-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Iloperidone Long-acting Injection (LAI) in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iloperidone | oral tablet, long-acting injection |
Timeline
- Start date
- 2021-01-13
- Primary completion
- 2022-08-30
- Completion
- 2022-08-30
- First posted
- 2021-01-15
- Last updated
- 2023-06-29
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04712734. Inclusion in this directory is not an endorsement.